Classification of ALL (synonym: lymphoblastic leukemia/lymphoma)
| B-ALL |
| B-ALL with recurrent genetic abnormalities |
| B-ALLwith t(9;22)(q34.1;q11.2)/BCR::ABL1 |
| with lymphoid only involvement |
| with multilineage involvement |
| B-ALLwith t(v;11q23.3)/KMT2A rearranged |
| B-ALL with t(12;21)(p13.2;q22.1)/ETV6::RUNX1 |
| B-ALL, hyperdiploid |
| B-ALL, low hypodiploid |
| B-ALL, near haploid |
| B-ALL with t(5;14)(q31.1;q32.3)/IL3::IGH |
| B-ALL with t(1;19)(q23.3;p13.3)/TCF3::PBX1 |
| B-ALL, BCR::ABL1–like, ABL-1 class rearranged |
| B-ALL, BCR::ABL1–like, JAK-STAT activated |
| B-ALL, BCR::ABL1–like, NOS |
| B-ALL with iAMP21 |
| B-ALL with MYC rearrangement |
| B-ALL with DUX4 rearrangement |
| B-ALL with MEF2D rearrangement |
| B-ALL with ZNF384(362) rearrangement |
| B-ALL with NUTM1 rearrangement |
| B-ALL with HLF rearrangement |
| B-ALL with UBTF::ATXN7L3/PAN3,CDX2 (“CDX2/UBTF”) |
| B-ALL with mutated IKZF1 N159Y |
| B-ALLwith mutated PAX5 P80R |
| Provisional entity: B-ALL, ETV6::RUNX1-like |
| Provisional entity: B-ALL, with PAX5 alteration |
| Provisional entity: B-ALL, with mutated ZEB2 (p.H1038R)/IGH::CEBPE |
| Provisional entity: B-ALL, ZNF384 rearranged-like |
| Provisional entity: B-ALL, KMT2A rearranged-like |
| B-ALL, NOS |
| T-ALL |
| Early T-cell precursor ALLwith BCL11B rearrangement |
| Early T-cell precursor ALL, NOS |
| T-ALL, NOS |
| Provisional entities (see supplemental Table 7) |
| Provisional entity: natural killer cell ALL |
| B-ALL |
| B-ALL with recurrent genetic abnormalities |
| B-ALLwith t(9;22)(q34.1;q11.2)/BCR::ABL1 |
| with lymphoid only involvement |
| with multilineage involvement |
| B-ALLwith t(v;11q23.3)/KMT2A rearranged |
| B-ALL with t(12;21)(p13.2;q22.1)/ETV6::RUNX1 |
| B-ALL, hyperdiploid |
| B-ALL, low hypodiploid |
| B-ALL, near haploid |
| B-ALL with t(5;14)(q31.1;q32.3)/IL3::IGH |
| B-ALL with t(1;19)(q23.3;p13.3)/TCF3::PBX1 |
| B-ALL, BCR::ABL1–like, ABL-1 class rearranged |
| B-ALL, BCR::ABL1–like, JAK-STAT activated |
| B-ALL, BCR::ABL1–like, NOS |
| B-ALL with iAMP21 |
| B-ALL with MYC rearrangement |
| B-ALL with DUX4 rearrangement |
| B-ALL with MEF2D rearrangement |
| B-ALL with ZNF384(362) rearrangement |
| B-ALL with NUTM1 rearrangement |
| B-ALL with HLF rearrangement |
| B-ALL with UBTF::ATXN7L3/PAN3,CDX2 (“CDX2/UBTF”) |
| B-ALL with mutated IKZF1 N159Y |
| B-ALLwith mutated PAX5 P80R |
| Provisional entity: B-ALL, ETV6::RUNX1-like |
| Provisional entity: B-ALL, with PAX5 alteration |
| Provisional entity: B-ALL, with mutated ZEB2 (p.H1038R)/IGH::CEBPE |
| Provisional entity: B-ALL, ZNF384 rearranged-like |
| Provisional entity: B-ALL, KMT2A rearranged-like |
| B-ALL, NOS |
| T-ALL |
| Early T-cell precursor ALLwith BCL11B rearrangement |
| Early T-cell precursor ALL, NOS |
| T-ALL, NOS |
| Provisional entities (see supplemental Table 7) |
| Provisional entity: natural killer cell ALL |